Butera Salvatore Thomas

Average Profitability
<0.0001%
Insider Buys Quantity
13
Insider Buys Sum
$218,771.50
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Butera Salvatore Thomas

According to the SEC Form 4 filings, Butera Salvatore Thomas, being in a position of

  1. CEO - Volition Veterinary at VolitionRx Limited,
    оver the last 12 months, has bought 20000 shares for $16,000, and sold 0 shares,
    over all time since 2021-11-16, has bought 112350 shares for $218,772, and sold 0 shares.

The largest purchase of all time was on 2021-11-16 and amounted to 20000 shares of VolitionRx Limited for $80,400.

Biography of Butera Salvatore Thomas

No biography is available at this moment.

2023-12-18PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0135%
$0.83$8,300-4.71%
2023-12-15PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0125%
$0.77$7,700-2.75%
2023-11-16PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0134%
$0.81$8,100-5.12%
2023-08-16PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
8,000
0.0107%
$1.21$9,680-35%
2023-06-02PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0172%
$1.59$15,900-41.49%
2022-12-19PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
5,000
0.009%
$2.27$11,350-33.7%
2022-12-12PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
4,350
0.008%
$2.09$9,092-25.12%
2022-11-28PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
5,000
0.009%
$2.21$11,050-29.86%
2022-08-23PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
5,000
0.009%
$1.60$8,000+7.86%
2022-08-22PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
5,000
0.0091%
$1.64$8,200+7.19%
2022-06-16PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0181%
$2.05$20,500-9.52%
2022-05-01PurchaseVolitionRx Limited
VNRX
CEO - Volition Veterinary
10,000
0.0137%
$2.05$20,500
2021-11-16PurchaseVolitionRx Limited
VNRX
20,000
0.0384%
$4.02$80,400-37.69%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.